Skip to main content
Erschienen in: Breast Cancer Research 1/2021

Open Access 01.12.2021 | Correction

Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

verfasst von: Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland III, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie Hunt, Amy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, Liewei Wang

Erschienen in: Breast Cancer Research | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13058-017-0920-8.
Correction to: Breast Cancer Research 19, 130 (2017)
/link?doi=10.1186/s13058-017-0920-8
Following publication of the original article [1], the authors would like to correct several typos in the article text:
1)
Page 4-right panel, Line 10: “The take rate was 51.3% (21/39; 95% CI: 34.8-67.6%) in TN subtype;”. Take rate should be 20/39 not 21/39. Percentages are correct.
 
2)
Page 4-right panel, Line 21: The last 2 sentences were corrected to be consistent with Table 2 as follows: “There was no take among the 18 luminal tumors. However, five of nine TN, and one of the eight HER2+ post-chemotherapy residual tumors took (verified breast tumor).”
 
3)
Page 4-right panel, Table 2: Total implanted for Luminal B should be 14 instead of 18. The total number of implanted 35 was correct.
 
4)
Page 5-left panel, Line 15: HER2+ tumors (7/17 vs. 2/15) should be (7/19 vs. 2/15). P-value is correct.
 
5)
Page 5-left panel, Line 20, The number of luminal tumors should be 18 instead of 22.
 
The authors sincerely apologize for any inconvenience.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
verfasst von
Jia Yu
Bo Qin
Ann M. Moyer
Jason P. Sinnwell
Kevin J. Thompson
John A. Copland III
Laura A. Marlow
James L. Miller
Ping Yin
Bowen Gao
Katherine Minter-Dykhouse
Xiaojia Tang
Sarah A. McLaughlin
Alvaro Moreno-Aspitia
Anthony Schweitzer
Yan Lu
Jason Hubbard
Donald W. Northfelt
Richard J. Gray
Katie Hunt
Amy L. Conners
Vera J. Suman
Krishna R. Kalari
James N. Ingle
Zhenkun Lou
Daniel W. Visscher
Richard Weinshilboum
Judy C. Boughey
Matthew P. Goetz
Liewei Wang
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2021
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-021-01420-z

Weitere Artikel der Ausgabe 1/2021

Breast Cancer Research 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.